Publications by authors named "E M Jolicoeur"
Background: Severe lung disease frequently presents with both refractory hypoxemia and right ventricular (RV) failure. Right ventricular assist device with an oxygenator (OxyRVAD) is an extracorporeal membrane oxygenation (ECMO) configuration of RV bypass that also supplements gas exchange. This systematic review summarises the available literature regarding the use of OxyRVAD in the setting of severe lung disease with associated RV failure.
View Article and Find Full Text PDFWe here describe the structure-based design of small molecule inhibitors of the type IV secretion system of . The secretion system is encoded by the pathogenicity island, and we chose Cagα, a hexameric ATPase and member of the family of VirB11-like proteins, as target for inhibitor design. We first solved the crystal structure of Cagα in a complex with the previously identified small molecule inhibitor 1G2.
View Article and Find Full Text PDFBackground: Given the limited access to invasive vasospastic reactivity testing in Western Countries, there is a need to further develop alternative non-invasive diagnostic methods for vasospastic angina (VSA). Hyperventilation testing (HVT) is defined as a class IIa recommendation to diagnose VSA by the Japanese Society of Cardiology.
Methods: In this systematic review and meta-analysis reported according to the PRISMA statement, we review the mechanisms, methods, modalities and diagnostic accuracy of non-invasive HVT for the diagnostic of VSA.
Article Synopsis
- The STICH3C trial aims to compare the effectiveness of coronary artery bypass grafting (CABG) and contemporary percutaneous coronary intervention (PCI) in patients with ischemic left ventricular dysfunction (iLVSD) and multivessel disease.
- It is a large international study involving around 754 participants, randomized to receive either CABG or PCI, focusing on patients with significant coronary artery disease and low heart function.
- The trial will assess overall patient outcomes, including survival rates and quality of life, over a follow-up period of up to 5 years, helping to guide future treatment protocols for this patient population.